

BioSpect


the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

Cadila Pharma's novel three-dose rabies vaccine ThRabis under trial for use in children

28 March 2023 | News

A game-changer in the global flight to eliminate rabies



Ahmedabad-based pharma major Cadila Pharmaceuticals had announced the launch of its novel three-dose recombinant nano-particle based rabies G protein vaccine last year, for adults.

The vaccine ThRabis, prepared by using Virus-Like Particle technology (VLP), is now undergoing clinical trials for use in children and shall be launched in the market very soon.

During an interaction with BioSpectrum, Dr Arani Chatterjee, Joint President, Cadila Pharma said, "Cadila is the first company in the world to develop a three-dose rabies vaccine in comparison to all the other vaccines which have five doses. This is a big matter of compliance for the patients. Currently, trials are going on for children for this vaccine which is already approved in adults."

Besides being convenient, ThRabis is an intramuscular vaccine and less painful for the recipients. It is also extremely convenient for doctors as it is a ready to use vaccine and does not require reconstitution prior to use